3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Sarcoma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Breast Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Neuroectodermal Tumors
2
Nervous System Diseases
2
Neoplasms, Neuroepithelial
2
Neoplasms, Nerve Tissue
2
Neoplasms
2
Liver Neoplasms
2
Gliosarcoma
2
Glioma
2
Glioblastoma
2
Colorectal Neoplasms
2
Carcinoma
2
Virus Diseases
1
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Pharyngeal Neoplasms
1
Ovarian Neoplasms
1
Otorhinolaryngologic Neoplasms
1
Nose Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Melanoma
1
Laryngeal Neoplasms
1
Interventions
Gemcitabine
2
valrubicin
1
pembrolizumab
1
liposomal doxorubicin
1
fludarabine phosphate
1
fludarabine
1
atezolizumab
1
Tumor Necrosis Factor-alpha
1
Oncolytic Virotherapy
1
Mitomycin
1
Interferons
1
Interferon-beta
1
Immune Checkpoint Inhibitors
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
1-dodecylpyridoxal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Adenoviridae Infections
×
Oncolytic Virotherapy
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled